GLP1_NEW
MEDI4166 400 mg injection once weekly
MEDI41_SC_400MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.67 (0.01 to 50.72) | 0.55 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.70 (0.19 to 19.91) | 0.57 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.95 (0.22 to 4.37) | 0.65 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.08 (0.00 to 1.05) | 0.92 |